Center for Drug Evaluation, Taiwan

FAQ

All

	No.		Class		Title
	21		Drug Substance		When submitting a DMF application, is it acceptable to submit only a batch manufacturing record and not performing the process validations using three industrial batches?
	22		Drug Substance		What is the definition of an API mix? What information must be provided while submitting a DMF for API mix?
	23		Drug Substance		If a potential genotoxic impurity is formed or introduced prior to the final step of the API manufacturing process, under what conditions can one waive routine control of the potential genotoxic impurity in the drug substance specification?
	24		Drug Substance		If a new drug substance is not yet listed in any pharmacopoeial monograph, how does one establish the acceptance criterion for total (organic) impurities in the drug substance specification?
	25		Drug Substance		Should the information of reference standards for all impurities listed in the specification of drug substance be provided in section 3.2.S.5 Reference Standards or Materials?
	26		Drug Substance		What information should be provided when there are multiple sources for a starting material?
	27		Drug Substance		What information on impurities in the drug substance should be included in CTD Section 3.2.S.3.2 when submitting a DMF/API application?
	28		Drug Substance		For starting materials that are not commercially available, what information should be provided on the production of starting materials?
	29		Drug Substance		According to section 3.2.S.2.2 in the DMF Technical Document Checklist annexed to the public promulgation no. DOH 1021401257, information such as "microorganism characterization" and "seed-lot system" should be provided if a drug substance is derived from fermentation process. What specific information should be provided for "microorganism characterization" and "seed-lot system"?
	30		Drug Substance		If metal catalysts are used in the manufacturing process of the drug substance, what data should be provided in order to waive routine control of such metal (elemental) impurities?

Page: 3/24 ‧ Total: 240

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |

Drugs Medical Devices Consultation Services Health Technology Assessment International Cooperation